ORG Wealth Partners LLC Boosts Holdings in AbbVie Inc. $ABBV

ORG Wealth Partners LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 14.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 22,082 shares of the company’s stock after purchasing an additional 2,708 shares during the quarter. AbbVie comprises about 1.2% of ORG Wealth Partners LLC’s holdings, making the stock its 11th biggest holding. ORG Wealth Partners LLC’s holdings in AbbVie were worth $5,119,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie during the second quarter valued at approximately $25,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie in the 2nd quarter worth $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie in the second quarter worth $36,000. Finally, Delos Wealth Advisors LLC bought a new position in shares of AbbVie during the second quarter valued at $39,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Price Performance

Shares of ABBV stock opened at $220.06 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a fifty day moving average price of $226.59 and a 200-day moving average price of $215.12. The company has a market cap of $388.93 billion, a price-to-earnings ratio of 166.71, a PEG ratio of 0.94 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 496.97%.

Analysts Set New Price Targets

Several research firms recently commented on ABBV. Raymond James Financial set a $256.00 price objective on AbbVie in a report on Monday, November 3rd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Guggenheim boosted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $246.89.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.